Figure 1
![Figure 1. Cumulative incidence for first SRE by bisphosphonate (ZOL vs CLO). (A) Patients who achieved a VGPR or less posttransplant (P = .048); PR (hazard ratio 0.74 [HR]; 95% confidence interval [CI], 0.52-1.05); VGPR (HR, 0.87; 95% CI, 0.60-1.27). (B) Patients who achieved a CR posttransplant (HR, 1.05, 95% CI, 0.82-1.35; P = .83).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/122/17/10.1182_blood-2013-04-498139/4/2974f1.jpeg?Expires=1735487340&Signature=j93jSIYeNx1ta52Cc21TCWb4rklienK92oMt9ZDDVDoyv7v~b5mld8qFfHGJmnq6amwWJnYYN5rXX1Wj2wT1D6xu~adehuzP14U3ya-WvsO4Suc8Js1QE992alJMZqZ-bAh7opD14qqzrBJEKF6Qjat~KQ-Nn7OZKalglEXfQKf7AMn0~D7310o3xHPKNathzFA92tASnzB69Eil-8~TZr7s4BUKAQnCiH1COfuBQlY1WJ2Cy2G7~Se7UKFFMwbdsH6TFKvO2OtIkFo-0TUaSsts1geubY~0YyJWedkNxGXKnXQbgsuuwiMWyl8TxOClX93JP6A6EmNW1QkEUf~6Ww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Cumulative incidence for first SRE by bisphosphonate (ZOL vs CLO). (A) Patients who achieved a VGPR or less posttransplant (P = .048); PR (hazard ratio 0.74 [HR]; 95% confidence interval [CI], 0.52-1.05); VGPR (HR, 0.87; 95% CI, 0.60-1.27). (B) Patients who achieved a CR posttransplant (HR, 1.05, 95% CI, 0.82-1.35; P = .83).
